Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Initiates Coverage On Osmotica Pharmaceuticals with Buy Rating, Announces Price Target of $5

Author: Benzinga Newsdesk | December 23, 2021 07:11am
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Osmotica Pharmaceuticals (NASDAQ:OSMT) with a Buy rating and announces Price Target of $5.

Posted In: OSMT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist